Biosense Webster Inc.
WATERLOO, Belgium, January 13, 2011 - Biosense Webster, Inc., a Johnson & Johnson company, and a worldwide
leader in the diagnosis and treatment of cardiac arrhythmias, announced the
successful completion of the first clinical cases with the new THERMOCOOL(R)
SMARTTOUCH(TM) Contact Force Sensing Catheter in the European Union,
following recent CE-marking of the product.
WATERLOO, Belgium, November 22, 2010 - According to data published last week in Circulation
Cardiovascular Quality and Outcomes, patients with a common heart rhythm
disorder, called atrial fibrillation, who were treated with catheter ablation
using the NaviStar(R)ThermoCool(R) Catheter, reported markedly fewer symptoms
and substantially improved quality of life than patients treated with
antiarrhythmia drugs at one year.
WATERLOO, Belgium, July 8, 2010 - Biosense Webster, Inc., a worldwide leader in the diagnosis and
treatment of cardiac arrhythmias, announces that more than 10 patients have
now been enrolled in the CLARITY-study ("CLARITY-AF"), comparing the
efficacy, safety and efficiency of CARTO(R) 3 System guided radiofrequency
ablation using the NAVISTAR(R) THERMOCOOL(R) catheter versus fluoroscopy
guided radiofrequency ablation using the Pulmonary Vein Ablation catheter(R)
(PVAC(R), Ablation Frontiers, Medtronic) in patients with paroxysmal atrial
fibrillation (Clinicaltrials.gov ID NCT01116557)
(www.clinicaltrials.gov/ct2/show/NCT01116557?term=PVAC&rank=1).
WATERLOO, Belgium, May 13, 2010 - Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment
of cardiac arrhythmias, announced today the completion of the first clinical
cases with the new THERMOCOOL(R) SF Irrigated Ablation catheter in the
European Union, following recent CE Mark approval.
DIAMOND BAR, California, May 13, 2010 - Biosense Webster, Inc.
